Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 10/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209867 | 0.83 | KIF11 (0.53) | KIF11GPR3 | |
| SCHEMBL2093550 | 0.83 | TRPV4 (0.41) | KIF11TRPV4 | |
| SCHEMBL185191 | 0.79 | KIF11 (0.58) | KIF11ARTRPV4SLC22A12VNN1 | |
| SCHEMBL29421437 | 0.79 | KIF11 (0.58) | KIF11ARTRPV4SLC22A12VNN1 | |
| SCHEMBL4927725 | 0.79 | KIF11 (0.41) | KIF11ARTRPV4SLC22A12MPL | |
| SCHEMBL30967278 | 0.79 | KIF11 (0.41) | KIF11ARTRPV4SLC22A12MPL | |
| SCHEMBL2520644 | 0.78 | KDR (0.51) | TRPV4 | |
| SCHEMBL5546385 | 0.78 | MAPT (0.41) | TRPV4 | |
| SCHEMBL6211552 | 0.78 | NOTUM (0.40) | KIF11ARTRPV4 | |
| SCHEMBL97003 | 0.75 | GRM5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20180265463-A1 | Vitamin D3 Derivatives and Pharmaceutical Use Thereof | KYOTO UNIVERSITY (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-3237377-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Kyoto University (JP) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103722-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2016-06-30 | — | — | WO | disclosed |
| CN-101312939-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1261603-B1 | FLAVONE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA SA (FR) | 2006-08-16 | — | — | EP | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005079769-A2 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| EP-1261603-A1 | FLAVONE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001064673-A1 | FLAVONE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | KIF11 4104/4885AR 587/4885TRPV4 979/4885 |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | KIF11 3592/4885AR 506/4885TRPV4 1568/4885 |
| US-20180265463-A1 | Vitamin D3 Derivatives and Pharmaceutical Use Thereof | VDR, CYP24A1, CYP2R1 | KIF11 3592/4885AR 506/4885TRPV4 1568/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | KIF11 2492/4885AR 618/4885TRPV4 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.